What is Enliven Therapeutics's short- term investments?

Enliven Therapeutics (ELVN) reported short- term investments of $320.22M in Q1 2026.

How has Enliven Therapeutics's short- term investments changed year-over-year?

Enliven Therapeutics's short- term investments increased by 70.5% year-over-year, from $187.85M to $320.22M.

Enliven Therapeutics ELVN Short- term Investments

Short- term Investments at other companies

Nuvation BioNUVB

——

ImmunityBio, Inc.IBRX

——

Nuvalent, Inc.NUVL

——

ExelixisEXEL

——

Gilead SciencesGILD

——

United TherapeuticsUTHR

——

Other financials

Income statement

See full

Operating income-$27.8M+12.2%

Net income-$23.6M+17.2%

EPS (diluted)-$0.38+33.3%

Balance sheet

See full

Cash & equivalents$132.2M+30.0%

Total debt$302.0K-56.9%

Total equity$453.4M+57.3%

Total assets$464.9M+53.6%

Cash flow

See full

Operating cash flow-$19.3M+20.0%

CapEx--100%

Free cash flow-$19.3M+20.1%

Valuation

See full

Market cap$3.47B+143%

Enterprise value$3.34B+156%

Returns & leverage

See full

Return on equity-26.6%-3.5pp

Debt / equity0×0.0×

Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Enliven Therapeutics's short- term investments?: Enliven Therapeutics (ELVN) reported short- term investments of $320.22M in Q1 2026.
How has Enliven Therapeutics's short- term investments changed year-over-year?: Enliven Therapeutics's short- term investments increased by 70.5% year-over-year, from $187.85M to $320.22M.